-
@ Yahoo! News - by layer3.news
2025-02-26 10:07:39
nostr:nprofile1qy3hwumn8ghj7un9d3shjtt5v4ehgmn9wshxkwrn9ekxz7t9wgejumn9waesqgzj8e74k6df32wrxaqsty6v5s42zvjxte0cn9cnzfllhjzr2v55tssjpv34
✍️ Akeso, a Chinese biotech company, has developed a new lung cancer drug that outperformed Keytruda, a blockbuster medication developed by Merck, in a clinical trial.
👉 Akeso's new lung cancer drug, Ivonescimab, outperformed Keytruda in a clinical trial.
👉 The drug was developed by Akeso, a Chinese biotech company.
👉 The trial was conducted in China and found that patients treated with Ivonescimab went 11.1 months before their tumors began to grow again, compared with 5.8 months for Keytruda.
👉 The achievement has sparked debate over the quality of domestically produced generic drugs in China.
👉 Some residents prefer imported drugs due to concerns over the quality of domestically produced medicine.
#MichelleXia,CEOofAkeso #RebeccaLiang,pharmaceuticalsanalystatABBernstein #CuiCui,managingdirectorofhealthcareresearchforJefferies #GuZhihao,Beijingresident #China #NorthAmerica #Europe #Beijing #health
nostr:nevent1qvzqqqqqqypzq53704dkn2v2nsehgyzexn9y92sny3j7t7yewycj0lauss6n99zuqy3hwumn8ghj7un9d3shjtt5v4ehgmn9wshxkwrn9ekxz7t9wgejumn9waesqg9dxvwzl0z53c6p2tp5vaurkqtx9gkmtyzyucfmgvszt94rs74h2sqhj55n